Hemorphin-7 binds to the angiotensin IV receptor, triggering multiple effects including cellular proliferation and memory enhancement. Hemorphins are endogenous peptides belonging to the family of atypical opioid peptides released from hydrolyzed hemoglobin. Hemorphin-7 is investigated as a potential biomarker for breast cancer.
